SG
SLXN

StoneX Group’s Silexion Therapeutics SLXN Stock Holding History

StoneX Group’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75
Closed -$9.11K – 1049
2025
Q2 		$9.11K Buy
+75
New +$10.2K ﹤0.01% 839

Other funds holding SLXN

MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

StoneX Group's SLXN Position: Q3 2025 in Review

StoneX Group sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 75 shares — an estimated $9.11K sold.

StoneX Group first reported a position in SLXN in Q2 2025 and held it in 1 quarter. The position peaked at $9.11K in Q2 2025. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

  • StoneX Group reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • StoneX Group sold 75 Silexion Therapeutics shares in Q3 2025, an estimated $9.11K.
  • StoneX Group first reported a position in Silexion Therapeutics in Q2 2025 and held it in 1 quarter.
  • StoneX Group's Silexion Therapeutics position peaked at $9.11K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.